CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: Switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant

Molecular Pharmacology

Volumn 68, Issue 3, 2005, Pages 644-651

  Hummel, Matthew A ^a   Locuson, Charles W ^a   Gannett, Peter M ^b   Rock, Dan A ^c   Mosher, Carrie M ^d   Rettie, Allan E ^d   Tracy, Timothy S ^a,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZBROMARONE; CYTOCHROME P450 2C9; FLURBIPROFEN;

ARTICLE; BINDING AFFINITY; CRYSTALLIZATION; DRUG EFFECT; ENZYME INHIBITION; GENE MUTATION; GENOTYPE; HYDROXYLATION; KINETICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; BENZBROMARONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA PRIMERS; DRUG INTERACTIONS; FLURBIPROFEN; GENOTYPE; HUMANS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; URICOSURIC AGENTS;

EID: 23944487499     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.013763     Document Type: Article

References (36)

1. Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88:5597-5601.
2. Cheesman MJ, Baer BR, Zheng YM, Gillam EM, and Rettie AE (2003) Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Arch Biochem Biophys 416:17-24.
3. Dickmann LJ, Locuson CW, Jones JP, and Rettie AE (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 65:842-850.
4. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, and Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387.
5. Egnell AC, Eriksson C, Albertson N, Houston B, and Boyer S (2003) Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307:878-887.
6. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
7. Haining RL, Hunter AP, Veronese ME, Trager WF, and Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458.
8. Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, and Rettie AE (1999) Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the Pi-stacking anchor site for warfarin binding. Biochemistry 38:3285-3292.
9. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, and Rettie AE (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 287:1690-1698.
10. Hummel MA, Dickmann LJ, Rettie AE, Haining RL, and Tracy TS (2004a) Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol 67:1831-1841.
11. Hummel MA, Gannett PM, Aguilar JS, and Tracy TS (2004b) Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 43:7207-7214.
12. Hutzler JM, Hauer MJ, and Tracy TS (2001) Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos 29:1029-1034.
13. Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, and Tracy TS (2003) Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys 410:16-24.
14. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
15. Lee CR, Goldstein JA, and Pieper JA (2002) Cytochrome P450 2C9 Polymorphisms: a Comprehensive Review of the in-Vitro and Human Data. Pharmacogenetics 12:251-263.
16. Locuson CW, Rock DA, and Jones JP (2004) Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 43:6948-6958.
17. Locuson CW, Wahlstrom JL, Rock DA, Rock DA, and Jones JP (2003) A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 31:967-971.
18. Marks BD, Thompson DV, Goossens TA, and Trubetskoy OV (2004) Highthroughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic vivid substrates. J Biomol Screen 9:439-449.
19. Mildvan AS and Gupta RK (1978) Nuclear relaxation measurements of the geometry of enzyme-bound substrates and analogs. Methods Enzymol 49:322-359.
20. Modi S, Paine MJ, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR, and Roberts GC (1996) A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35:4540-4550.
21. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, and Kitada M (2002) Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos 30:534-540.
22. Poli-Scaife S, Attias R, Dansette PM, and Mansuy D (1997) The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 36:12672-12682.
23. Regal KA and Nelson SD (2000) Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements. Arch Biochem Biophys 384:47-58.
24. Shafirovich V, Mock S, Kolbanovskiy A, and Geacintov NE (2002) Photochemically catalyzed generation of site-specific 8-nitroguanine adducts in DNA by the reaction of long-lived neutral guanine radicals with nitrogen dioxide. Chem Res Toxicol 15:591-597.
25. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, and Rushmore TH (2001) A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256-2262.
26. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
27. Shou M, Mei Q, EttoreMWJr, Dai R, Baillie TA, and Rushmore TH (1999) Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 340:845-853.
28. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, and Rettie AE (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361-367.
29. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, and Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
30. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, and Dickmann LJ (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385-390.
31. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, and Korzekwa KR (1996) Studies of flurbiprofen 4′-hydroxylation - additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52:1305-1309.
32. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, and Korzekwa KR (1995) Role of cytochrome P450 2C9 and an allelic variant in the 4′- hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49:1269-1275.
33. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J Biol Chem 279:35630-35637.
34. Wienkers LC (2002) Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. Eur J Pharm Sci 15:239-242.
35. Williams PA, Cosme J, Ward A, Angove HC, Matak VD, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (Lond) 424:464-468.
36. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen and diclofenac by human liver microsomes. Biochem Pharmacol 56:243-251.